A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: Patients with psoriasis value rapid and complete skin clearance. No head-to-head studies have focused on early responses to interleukin (IL)-17 vs. IL-23 inhibitors. OBJECTIVES: To compare early and complete skin clearance by the IL-17A inhibitor ixekizumab vs. the IL-23p19 inhibitor guselkumab. METHODS: IXORA-R, a 24-week, randomized, double-blinded study, enrolled adults with moderate-to-severe plaque psoriasis [static Physician's Global Assessment of Disease (sPGA) score of ≥ 3, Psoriasis Area and Severity Index (PASI) ≥ 12, and ≥ 10% body surface area]. Patients were randomized (1 : 1) to receive the approved dose of subcutaneous ixekizumab or guselkumab. Primary end point was 100% improvement in PASI (PASI 100) at week 12. Major secondary end points included other levels of improved PASI and sPGA at different time points. Comparisons were made using the Cochran-Mantel-Haenszel test with a multiple testing strategy. Nonresponder imputation was used for missing data. After the completion of the study, the final secondary end point (PASI 100 at 24 weeks) and safety data through week 24 will be reported. RESULTS: In total, 1027 patients were randomized. The primary end point PASI 100 at week 12 was met [215/520 ixekizumab (41%); 126/507 guselkumab (25%); P < 0·001]. All major secondary end points measured up to week 12 were met, including PASI 50 at week 1 and PASI 75 at week 2. Serious adverse event frequency was 3% for each group; no new safety signals were identified. CONCLUSIONS: Ixekizumab was superior to guselkumab for rapidly improving signs and symptoms in patients with moderate-to-severe plaque psoriasis by week 12. Adverse events were similar to previous ixekizumab and guselkumab studies. Compared with the IL-23 inhibitor guselkumab, ixekizumab can offer complete skin clearance more rapidly to patients with moderate-to-severe plaque psoriasis. What's already known about this topic? Patients with plaque psoriasis desire both high levels of clearance and rapid onset of treatment effects. Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, has demonstrated greater and faster skin clearance than etanercept and ustekinumab, with consistent long-term efficacy, safety and durability of response. Clinical trial data and systematic reviews have suggested that IL-17 inhibitors can improve a patient's psoriasis more rapidly than IL-23 inhibitors. What does this study add? The head-to-head study design directly compares the efficacy and speed of response of ixekizumab and the IL-23 inhibitor guselkumab in moderate-to-severe plaque psoriasis. The primary end point was met, showing superiority of ixekizumab over guselkumab for achieving complete skin clearance at week 12. The safety profile of ixekizumab was consistent with previous studies. Ixekizumab can deliver patients complete skin clearance and improved quality of life more rapidly than guselkumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gordon, K. B., Foley, P., Krueger, J. G., Pinter, A., Reich, K., Vender, R., Vanvoorden, V., Madden, C., White, K., Cioffi, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00126-4 · Cited by 295
Self-citationThe Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192
Data extraction for evidence synthesis using a large language model: A proof-of-concept study
Gartlehner, G., Kahwati, L., Hilscher, R., Thomas, I., Kugley, S., Crotty, K., Viswanathan, M., Nussbaumer‐Streit, B., Booth, G., Erskine, N., et al. (2024) · Research Synthesis Methods · doi:10.1002/jrsm.1710 · Cited by 164
“When we conducted a sensitivity analysis without the three study reports that we used for prompt engineering, 21,25,28 the accuracy changed to 95.5%.”
InfluentialPerformance of two large language models for data extraction in evidence synthesis
Konet, A., Thomas, I., Gartlehner, G., Kahwati, L., Hilscher, R., Kugley, S., Crotty, K., Viswanathan, M., & Chew, R. (2024) · Research Synthesis Methods · doi:10.1002/jrsm.1732 · Cited by 79
Two-year US Pharmacovigilance report on Brodalumab
Lebwohl, M., Leonardi, C., Wu, J. J., Armstrong, A., Rawnsley, N., Merchant, M., Alexander, B., & Jacobson, A. (2021) · Dermatology and Therapy · doi:10.1007/s13555-020-00472-x · Cited by 24
Self-citation
Metadata
- Authors
- Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K. B., Ferris, L. K., Langley, R. G., Tada, Y., Lima, R. G., Elmaraghy, H., Gallo, G., Renda, L., Park, S. Y., Burge, R., Bagel, J., the IXORA‐R Study Group, Vender, R., Lomaga, M. A., Delorme, I., Hong, C., Langley, R. L., Albrecht, L., Guenther, L., Maari, C., Papp, K., Singh Ohson, K. K., Barber, K., Lynde, C., Gupta, A., Rosoph, L., Gauthier, J., Gooderham, M., Wasel, N., Raman, M., Wiseman, M., Greenstein, D., Jarell, A., Moon, C., Clark, L., Jazayeri, S. S., Bukhalo, M., Moore, A., Hamilton, T. K., Gewirtzman, A., Hazan, L., Crowley, J., Teller, C., Zirwas, M., Smith, S. R., Christine Lee, M., Tyring, S., Lee, P., Dhawan, S., Leonardi, C., Jesus, A. P., McFalda, W., Frankel, E., Yamauchi, P., Fretzin, S., Serrao, R., Schlesinger, T., Gottlieb, S., Jenkin, P., Gharib, R., Davis, S., Nami, N., Draelos, Z. D., Godwin, L., Owen, C., Landis, M., Abramovits, W., Sanchez‐Rivera, S., Van Voorhees, A., Fivenson, D., Kerdel, F., Forman, S. B., Weinberg, J., Gonzalez‐Chavez, J., Boyce, B., Stein‐Gold, L., Hudson, C., Brown, C., Coggi, J., Feser, C., Forconi, R., Johnson, S., McCune, M., Green, L., Madkan, V., Shipp, D. M., Gordon, K., Waibel, J., Soto‐Raices, O., Cather, J., Miller, S., Scott, J., Young, D., Kaffenberger, J., Yokum, K., Zook, M., Blauvelt, A., Truett, A., Schmieder, G., McCracken, G., McElgunn, P., Herrmann, J., Suchniak, J. M., Appel, J., Barranco, E., Lee, M., Bagel, J., Osman, L., Cauthen, A., Sadick, N., De La Torre, E., Taylor, K., Cohen, D., Harris, H. H., Soung, J., Dimitropoulos, V., Miller, S., Barnes, C., Jumean‐Haddad, R., Bruce, S., Cheung, L., Guenthner, S., Gaspari, A., Laquer, V., Krell, J. M., Jacobs, S., Nahm, W., Korman, N., Elewski, B., Ferris, L., Duffin, K. C., Pariser, D., Johnson, B., Wallace, P., Travers, J., & Fried, R.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01-15
- Volume
- 182
- Issue
- 6
- Pages
- 1348-1358
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W2997875868
- Cited by
- 175
- References
- 0
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. https://app.cochat.ai/papers/10.1111/bjd.18851
- The paper
- Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K. B., Ferris, L. K., Langley, R. G., Tada, Y., Lima, R. G., Elmaraghy, H., Gallo, G., Renda, L., Park, S. Y., Burge, R., Bagel, J., the IXORA‐R Study Group, Vender, R., . . . Fried, R. (2020). A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. British Journal of Dermatology. https://doi.org/10.1111/bjd.18851
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.